Anti-thymocyte globulin/G-CSF treatment preserves β cell function in patients with established type 1 diabetes

BACKGROUND. Previous efforts to preserve β cell function in individuals with type 1 diabetes (T1D) have focused largely on the use of single immunomodulatory agents administered within 100 days of diagnosis. Based on human and preclinical studies, we hypothesized that a combination of low-dose anti-...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Invest
Autors principals: Haller, Michael J., Gitelman, Stephen E., Gottlieb, Peter A., Michels, Aaron W., Rosenthal, Stephen M., Shuster, Jonathan J., Zou, Baiming, Brusko, Todd M., Hulme, Maigan A., Wasserfall, Clive H., Mathews, Clayton E., Atkinson, Mark A., Schatz, Desmond A.
Format: Artigo
Idioma:Inglês
Publicat: American Society for Clinical Investigation 2014
Matèries:
Clinical Medicine
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC4382237/
https://ncbi.nlm.nih.gov/pubmed/25500887
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI78492
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars